Stem Cells and Regenerative Medicine in Asia, drug development, supporting cell therapy, Asian companies strategies.
Posted on November 13, 2012
By: Mahendra Rao, Head of Center for Regenerative Medicine.
NIH
Abstract The current model of funding for drug development, while successful, is difficult to replicate in a regenerative medicine model. This difficulty has led to the development of different models for developing and supporting cell therapy. Hampered by fewer regulations, Asian hospitals and comp...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
bioreactor, Cord Blood Banking, cosmeceutical, drug development, FDA, Hematopoietic cell transplantation (HCT), hematopoietic stem cells, human embryonic stem cells (hES), immunotherapy, Induced pluripotent stem cells, multiple sclerosis, spinal cord injury, Stem cell, stroke
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
